Skip to main content
PMC home page
Journal of Psychiatry & Neuroscience : JPN logoLink to Journal of Psychiatry & Neuroscience : JPN
. 1993 Mar;18(2):61–66.

The manic syndrome: factors which may predict a patient's response to lithium, carbamazepine and valproate.

S C Dilsaver 1, A C Swann 1, A M Shoaib 1, T C Bowers 1
PMCID: PMC1188487  PMID: 8461283

Abstract

Studies suggest that 80% to 90% of all patients in the manic state respond to lithium provided that they are relatively free of dysphoria ("pure mania"). In contrast, less than 40% of individuals in the manic state who cycle rapidly or are substantially dysphoric ("dysphoric mania") respond to lithium. These patients appear to be more responsive to carbamazepine and valproate. The authors conclude that carbamazepine and valproate are the drugs of choice if one desires to treat a rapidly cycling individual or patient with dysphoric mania with just one agent. However, they emphasize that a prospective study designed to identify the predictors of response of primary mania to lithium, carbamazepine and valproate is required. Studies assessing the relative value of lithium, carbamazepine or valproate as prophylactic agents in the care of patients with specific subtypes of mania are also needed. These studies would address the most important issues confronting researchers interested in the drug treatment of mania.

Full text

PDF
63

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Angst J., Weis P., Grof P., Baastrup P. C., Schou M. Lithium prophylaxis in recurrent affective disorders. Br J Psychiatry. 1970 Jun;116(535):604–614. doi: 10.1192/bjp.116.535.604. [DOI] [PubMed] [Google Scholar]
  2. Ballenger J. C., Post R. M. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry. 1980 Jul;137(7):782–790. doi: 10.1176/ajp.137.7.782. [DOI] [PubMed] [Google Scholar]
  3. Ballenger J. C., Post R. M. Therapeutic effects of carbamazepine in affective illness: a preliminary report. Commun Psychopharmacol. 1978;2(2):159–175. [PubMed] [Google Scholar]
  4. Beigel A., Murphy D. L. Unipolar and bipolar affective illness. Differences in clinical characteristics accompanying depression. Arch Gen Psychiatry. 1971 Mar;24(3):215–220. doi: 10.1001/archpsyc.1971.01750090021003. [DOI] [PubMed] [Google Scholar]
  5. Calabrese J. R., Delucchi G. A. Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry. 1990 Apr;147(4):431–434. doi: 10.1176/ajp.147.4.431. [DOI] [PubMed] [Google Scholar]
  6. Dunner D. L., Fieve R. R. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry. 1974 Feb;30(2):229–233. doi: 10.1001/archpsyc.1974.01760080077013. [DOI] [PubMed] [Google Scholar]
  7. Dunner D. L., Patrick V., Fieve R. R. Rapid cycling manic depressive patients. Compr Psychiatry. 1977 Nov-Dec;18(6):561–566. doi: 10.1016/s0010-440x(97)90006-7. [DOI] [PubMed] [Google Scholar]
  8. Emrich H. M., von Zerssen D., Kissling W., Möller H. J., Windorfer A. Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders. Arch Psychiatr Nervenkr (1970) 1980;229(1):1–16. doi: 10.1007/BF00343800. [DOI] [PubMed] [Google Scholar]
  9. Freeman T. W., Clothier J. L., Pazzaglia P., Lesem M. D., Swann A. C. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry. 1992 Jan;149(1):108–111. doi: 10.1176/ajp.149.1.108. [DOI] [PubMed] [Google Scholar]
  10. Himmelhoch J. M., Garfinkel M. E. Sources of lithium resistance in mixed mania. Psychopharmacol Bull. 1986;22(3):613–620. [PubMed] [Google Scholar]
  11. Himmelhoch J. M., Mulla D., Neil J. F., Detre T. P., Kupfer D. J. Incidence and signficiance of mixed affective states in a bipolar population. Arch Gen Psychiatry. 1976 Sep;33(9):1062–1066. doi: 10.1001/archpsyc.1976.01770090052004. [DOI] [PubMed] [Google Scholar]
  12. Jamison K. R., Gerner R. H., Goodwin F. K. Patient and physician attitudes toward lithium: relationship to compliance. Arch Gen Psychiatry. 1979 Jul 20;36(8 Spec No):866–869. doi: 10.1001/archpsyc.1979.01780080040011. [DOI] [PubMed] [Google Scholar]
  13. Joyce P. R. Carbamazepine in rapid cycling bipolar affective disorder. Int Clin Psychopharmacol. 1988 Apr;3(2):123–129. doi: 10.1097/00004850-198804000-00003. [DOI] [PubMed] [Google Scholar]
  14. Keller M. B., Lavori P. W., Coryell W., Andreasen N. C., Endicott J., Clayton P. J., Klerman G. L., Hirschfeld R. M. Differential outcome of pure manic, mixed/cycling, and pure depressive episodes in patients with bipolar illness. JAMA. 1986 Jun 13;255(22):3138–3142. [PubMed] [Google Scholar]
  15. Kukopulos A., Caliari B., Tundo A., Minnai G., Floris G., Reginaldi D., Tondo L. Rapid cyclers, temperament, and antidepressants. Compr Psychiatry. 1983 May-Jun;24(3):249–258. doi: 10.1016/0010-440x(83)90076-7. [DOI] [PubMed] [Google Scholar]
  16. Lerer B., Moore N., Meyendorff E., Cho S. R., Gershon S. Carbamazepine versus lithium in mania: a double-blind study. J Clin Psychiatry. 1987 Mar;48(3):89–93. [PubMed] [Google Scholar]
  17. Lusznat R. M., Murphy D. P., Nunn C. M. Carbamazepine vs lithium in the treatment and prophylaxis of mania. Br J Psychiatry. 1988 Aug;153:198–204. doi: 10.1192/bjp.153.2.198. [DOI] [PubMed] [Google Scholar]
  18. Maarbjerg K., Aagaard J., Vestergaard P. Adherence to lithium prophylaxis: I. Clinical predictors and patient's reasons for nonadherence. Pharmacopsychiatry. 1988 May;21(3):121–125. doi: 10.1055/s-2007-1014662. [DOI] [PubMed] [Google Scholar]
  19. Maj M., Pirozzi R., Kemali D. Long-term outcome of lithium prophylaxis in patients initially classified as complete responders. Psychopharmacology (Berl) 1989;98(4):535–538. doi: 10.1007/BF00441955. [DOI] [PubMed] [Google Scholar]
  20. McElroy S. L., Keck P. E., Jr, Pope H. G., Jr, Hudson J. I. Valproate in the treatment of bipolar disorder: literature review and clinical guidelines. J Clin Psychopharmacol. 1992 Feb;12(1 Suppl):42S–52S. doi: 10.1097/00004714-199202001-00007. [DOI] [PubMed] [Google Scholar]
  21. McElroy S. L., Keck P. E., Jr, Pope H. G., Jr, Hudson J. I. Valproate in the treatment of rapid-cycling bipolar disorder. J Clin Psychopharmacol. 1988 Aug;8(4):275–279. [PubMed] [Google Scholar]
  22. McElroy S. L., Keck P. E., Jr, Pope H. G., Jr Sodium valproate: its use in primary psychiatric disorders. J Clin Psychopharmacol. 1987 Feb;7(1):16–24. [PubMed] [Google Scholar]
  23. Okuma T., Inanaga K., Otsuki S., Sarai K., Takahashi R., Hazama H., Mori A., Watanabe M. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study. Psychopharmacology (Berl) 1979;66(3):211–217. doi: 10.1007/BF00428308. [DOI] [PubMed] [Google Scholar]
  24. Okuma T., Inanaga K., Otsuki S., Sarai K., Takahashi R., Hazama H., Mori A., Watanabe S. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology (Berl) 1981;73(1):95–96. doi: 10.1007/BF00431111. [DOI] [PubMed] [Google Scholar]
  25. Polatin P., Fieve R. R. Patient rejection of lithium carbonate prophylaxis. JAMA. 1971 Nov 8;218(6):864–866. [PubMed] [Google Scholar]
  26. Pope H. G., Jr, McElroy S. L., Keck P. E., Jr, Hudson J. I. Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry. 1991 Jan;48(1):62–68. doi: 10.1001/archpsyc.1991.01810250064008. [DOI] [PubMed] [Google Scholar]
  27. Post R. M., Berrettini W., Uhde T. W., Kellner C. Selective response to the anticonvulsant carbamazepine in manic-depressive illness: a case study. J Clin Psychopharmacol. 1984 Aug;4(4):178–185. [PubMed] [Google Scholar]
  28. Post R. M., Rubinow D. R., Uhde T. W., Roy-Byrne P. P., Linnoila M., Rosoff A., Cowdry R. Dysphoric mania. Clinical and biological correlates. Arch Gen Psychiatry. 1989 Apr;46(4):353–358. doi: 10.1001/archpsyc.1989.01810040059009. [DOI] [PubMed] [Google Scholar]
  29. Post R. M., Uhde T. W., Roy-Byrne P. P., Joffe R. T. Correlates of antimanic response to carbamazepine. Psychiatry Res. 1987 May;21(1):71–83. doi: 10.1016/0165-1781(87)90064-3. [DOI] [PubMed] [Google Scholar]
  30. Prien R. F., Caffey E. M., Jr, Klett C. J. Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. Arch Gen Psychiatry. 1972 Feb;26(2):146–153. doi: 10.1001/archpsyc.1972.01750200050011. [DOI] [PubMed] [Google Scholar]
  31. Prien R. F., Gelenberg A. J. Alternatives to lithium for preventive treatment of bipolar disorder. Am J Psychiatry. 1989 Jul;146(7):840–848. doi: 10.1176/ajp.146.7.840. [DOI] [PubMed] [Google Scholar]
  32. Prien R. F., Himmelhoch J. M., Kupfer D. J. Treatment of mixed mania. J Affect Disord. 1988 Jul-Aug;15(1):9–15. doi: 10.1016/0165-0327(88)90003-1. [DOI] [PubMed] [Google Scholar]
  33. Prien R. F. Methods and models for placebo use in pharmacotherapeutic trials. Psychopharmacol Bull. 1988;24(1):4–8. [PubMed] [Google Scholar]
  34. SCHOU M., JUEL-NIELSEN N., STROMGREN E., VOLDBY H. The treatment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiatry. 1954 Nov;17(4):250–260. doi: 10.1136/jnnp.17.4.250. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Secunda S. K., Katz M. M., Swann A., Koslow S. H., Maas J. W., Chuang S., Croughan J. Mania. Diagnosis, state measurement and prediction of treatment response. J Affect Disord. 1985 Mar-Apr;8(2):113–121. doi: 10.1016/0165-0327(85)90033-3. [DOI] [PubMed] [Google Scholar]
  36. Secunda S., Koslow S. H., Redmond D. E., Garver D., Ramsey T. A., Croughan J., Kocsis J., Hanin I., Lieberman K., Casper R. Biological component of the NIMH clinical research branch collaborative program on the psychobiology of depression: II. Methodology and data analysis. Psychol Med. 1980 Nov;10(4):777–793. doi: 10.1017/s0033291700055069. [DOI] [PubMed] [Google Scholar]
  37. Sedler M. J. Falret's discovery: the origin of the concept of bipolar affective illness. Translated by M. J. Sedler and Eric C. Dessain. Am J Psychiatry. 1983 Sep;140(9):1127–1133. doi: 10.1176/ajp.140.9.1127. [DOI] [PubMed] [Google Scholar]
  38. Swann A. C., Secunda S. K., Katz M. M., Koslow S. H., Maas J. W., Chang S., Robins E. Lithium treatment of mania: clinical characteristics, specificity of symptom change, and outcome. Psychiatry Res. 1986 Jun;18(2):127–141. doi: 10.1016/0165-1781(86)90025-9. [DOI] [PubMed] [Google Scholar]
  39. Wehr T. A., Sack D. A., Rosenthal N. E., Cowdry R. W. Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients. Am J Psychiatry. 1988 Feb;145(2):179–184. doi: 10.1176/ajp.145.2.179. [DOI] [PubMed] [Google Scholar]
  40. Weissman M. M., Leaf P. J., Tischler G. L., Blazer D. G., Karno M., Bruce M. L., Florio L. P. Affective disorders in five United States communities. Psychol Med. 1988 Feb;18(1):141–153. doi: 10.1017/s0033291700001975. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Psychiatry and Neuroscience are provided here courtesy of Canadian Medical Association

RESOURCES